Tofacitinib in cardiovascular outcomes: friend or foe?

Rheumatology (Oxford). 2020 Aug 1;59(8):1797-1798. doi: 10.1093/rheumatology/keaa090.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Rheumatoid / drug therapy*
  • Cardiovascular Diseases / chemically induced*
  • Colitis, Ulcerative / drug therapy*
  • Humans
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Piperidines
  • Pyrimidines
  • tofacitinib